Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
AZD-1705 by AstraZeneca for Dyslipidemia: Likelihood of Approval
AZD-1705 is under clinical development by AstraZeneca and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I drugs...